Overview

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to compare the safety and efficacy of different induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in renal transplant recipients treated with tacrolimus, mycophenolate mofetil (MMF) and a rapid steroid withdrawal.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Alemtuzumab
Antibodies, Monoclonal
Antilymphocyte Serum
Basiliximab
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus
Thymoglobulin
Criteria
Inclusion Criteria:

- Recipient of a primary or re-transplanted deceased donor kidney or a primary or
re-transplanted non-human leukocyte antigen (HLA) living donor kidney (ie., HLA
identical or 0 antigen mismatch deceased donor kidneys are allowed).

Exclusion Criteria:

- Patient has previously received an organ transplant other than a kidney

- Patient receiving chronic steroid therapy at time of transplant